Results 11 to 20 of about 30,070 (260)

IL-4 Serum Level Estimation in Myeloproliferative Neoplasm Patients

مجلة مركز بحوث التقنيات الاحيائية, 2022
Back Ground: Myeloproliferative neoplasm (MPN) is a long-term blood disease that has an excess production of mature hematopoietic pluripotent stem cells in the bone marrow. In the early fifties, W.
Ahmed Rushdi Abdullah
doaj   +3 more sources

Autoimmunity and the risk of myeloproliferative neoplasms

Haematologica, 2010
The causes of myeloproliferative neoplasm (MPN) are unknown. We conducted a large population-based study including 11,039 myeloproliferative neoplasm patients and 43,550 matched controls with the aim of assessing the associations between a personal ...
Sigurdur Y. Kristinsson, Ola Landgren, Jan Samuelsson, Magnus Björkholm, Lynn R. Goldin   +4 more
doaj   +2 more sources

Neutrophilic Dermatosis of the Dorsal Hands Associated with a “Myeloproliferative Neoplasm, Unclassifiable“ and a Simultaneous Cancer of Colon

Acta Medica, 2010
Neutrophilic dermatosis of the dorsal hands is a variant of Sweet's syndrome. We herein describe an 83-year old woman with a neutrophilic dermatosis of the dorsal hands associated with a "myeloproliferative neoplasm, unclassifiable" and a simultaneous ...
Francisco José Fernández-Fernández, Juan Carlos Álvarez – Fernández, Esperanza Romero – Picos, Juan Antonio Garrido, Pascual Sesma   +4 more
doaj   +2 more sources

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency [PDF]

Haematologica, 2016
Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation.
Zohar Sachs, Raha A. Been, Krista J. DeCoursin, Hanh T. Nguyen, Nurul A. Mohd Hassan, Klara E. Noble-Orcutt, Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, Diane E. Hasz, Kelly J. Morgan, Margaret L. MacMillan, Kevin M. Shannon, David A. Largaespada, Stephen M. Wiesner   +16 more
doaj   +2 more sources

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort [PDF]

Haematologica, 2019
Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this ...
Johanne M. Holst, Trine L. Plesner, Martin B. Pedersen, Henrik Frederiksen, Michael B. Møller, Michael R. Clausen, Marcus C. Hansen, Stephen Jacques Hamilton-Dutoit, Peter Nørgaard, Preben Johansen, Tobias Ramm Eberlein, Bo K. Mortensen, Gustav Mathiasen, Andreas Øvlisen, Rui Wang, Chao Wang, Weiwei Zhang, Hans Beier Ommen, Jesper Stentoft, Maja Ludvigsen, Wayne Tam, Wing C. Chan, Giorgio Inghirami, Francesco d'Amore   +23 more
doaj   +2 more sources

Chronic myeloproliferative neoplasm in adulthood in CBL syndrome harboring a splice‐site CBL variant alongside a novel constitutional CSF3R variant

eJHaem
Casitas B‐cell lineage (CBL) syndrome is a rare RASopathy known to predispose to CBL‐mutated juvenile myelomonocytic leukemia (JMML) in childhood. Adulthood acute myeloid leukemia arising out of a genetic aberrancies consistent with prior CBL‐mutated ...
George Mason, Rhian Aghajani, Brieanna Dance, Jad Othman, Linda Goodwin, William Stevenson, Naomi Mackinlay   +6 more
doaj   +2 more sources

The Microenvironment in Myeloproliferative Neoplasms [PDF]

Hematology/Oncology Clinics of North America, 2021
Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN.
Ramanathan, Gajalakshmi, Fleischman, Angela G   +1 more
openaire   +3 more sources

Myeloproliferative neoplasms [PDF]

Clinical Medicine, 2013
The myeloproliferative neoplasms that are associated with the JAK2 mutation are a heterogeneous group of disorders. The additional mutations that result in the clinical phenotype are still the subject of research. As more than one mutation is involved, and as JAK2 has a necessary physiological role (unlike BCR-ABL), the development of targeted therapy ...
Amy, Publicover, Patrick, Medd
openaire   +3 more sources

Epigenetics in myeloproliferative neoplasms

Frontiers in Oncology, 2023
The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence ...
Greenfield, Graeme, McMullin, Mary Frances   +1 more
openaire   +4 more sources

Genomics of Myeloproliferative Neoplasms [PDF]

Journal of Clinical Oncology, 2017
Myeloproliferative neoplasms (MPNs) are a group of related clonal hematologic disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR -ABL1–negative MPNs and a unifying therapeutic target. In
Zoi, Katerina, Cross, Nicholas
openaire   +2 more sources